Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr

Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023

Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr

Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023

Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer

AbbVie launches Produodopa for treatment of parkinson's disease in EU

Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)